Back to Treatments

Treatment

Cetuximab (Targeted Therapy)

2
Conditions
5
Trials
70K
Participants
50%
Average Safety

Condition Evidence

Larynx cancer

3 trials · 20K participants

65% effectiveness · 45% safety

Lip and oral cavity cancer

2 trials · 50K participants

65% effectiveness · 55% safety
Cetuximab (Targeted Therapy) | DFDA